This study tests a new drug called PMN310 in people with early Alzheimer's disease. The goal is to see if it is safe and if it can reduce signs of the disease in the brain. About 144 participants will receive multiple doses of the drug or a placebo. This is an early-phase trial, …
Phase: PHASE1 • Sponsor: ProMis Neurosciences, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC